These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Response to: ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. McNeill A Mov Disord; 2010 Oct; 25(13):2253. PubMed ID: 20740487 [No Abstract] [Full Text] [Related]
3. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Brüggemann N; Hagenah J; Reetz K; Schmidt A; Kasten M; Buchmann I; Eckerle S; Bähre M; Münchau A; Djarmati A; van der Vegt J; Siebner H; Binkofski F; Ramirez A; Behrens MI; Klein C Arch Neurol; 2010 Nov; 67(11):1357-63. PubMed ID: 21060012 [TBL] [Abstract][Full Text] [Related]
4. Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts. Kruer MC; Paudel R; Wagoner W; Sanford L; Kara E; Gregory A; Foltynie T; Lees A; Bhatia K; Hardy J; Hayflick SJ; Houlden H Neurosci Lett; 2012 Aug; 523(1):35-8. PubMed ID: 22743658 [TBL] [Abstract][Full Text] [Related]
5. Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay. Kırımtay K; Temizci B; Gültekin M; Yapıcı Z; Karabay A Brain Res; 2021 Jan; 1750():147167. PubMed ID: 33091395 [TBL] [Abstract][Full Text] [Related]
6. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Chien HF; Bonifati V; Barbosa ER Mov Disord; 2011 Jun; 26(7):1364-5. PubMed ID: 21469196 [No Abstract] [Full Text] [Related]
7. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78). Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957 [TBL] [Abstract][Full Text] [Related]
8. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Paisán-Ruiz C; Guevara R; Federoff M; Hanagasi H; Sina F; Elahi E; Schneider SA; Schwingenschuh P; Bajaj N; Emre M; Singleton AB; Hardy J; Bhatia KP; Brandner S; Lees AJ; Houlden H Mov Disord; 2010 Sep; 25(12):1791-800. PubMed ID: 20669327 [TBL] [Abstract][Full Text] [Related]
9. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Behrens MI; Brüggemann N; Chana P; Venegas P; Kägi M; Parrao T; Orellana P; Garrido C; Rojas CV; Hauke J; Hahnen E; González R; Seleme N; Fernández V; Schmidt A; Binkofski F; Kömpf D; Kubisch C; Hagenah J; Klein C; Ramirez A Mov Disord; 2010 Sep; 25(12):1929-37. PubMed ID: 20683840 [TBL] [Abstract][Full Text] [Related]
10. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review. Yang X; Xu Y Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640 [TBL] [Abstract][Full Text] [Related]
11. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Santoro L; Breedveld GJ; Manganelli F; Iodice R; Pisciotta C; Nolano M; Punzo F; Quarantelli M; Pappatà S; Di Fonzo A; Oostra BA; Bonifati V Neurogenetics; 2011 Feb; 12(1):33-9. PubMed ID: 20853184 [TBL] [Abstract][Full Text] [Related]
12. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062 [TBL] [Abstract][Full Text] [Related]
13. Neuropathologic Findings in a Patient With Juvenile-Onset Levodopa-Responsive Parkinsonism Due to Chien HF; Rodriguez RD; Bonifati V; Nitrini R; Pasqualucci CA; Gelpi E; Barbosa ER Neurology; 2021 Oct; 97(16):763-766. PubMed ID: 34475127 [TBL] [Abstract][Full Text] [Related]
14. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2. Park JS; Sue CM Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689 [TBL] [Abstract][Full Text] [Related]
16. Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation. Martino D; Melzi V; Franco G; Kandasamy N; Monfrini E; Di Fonzo A Parkinsonism Relat Disord; 2015 Nov; 21(11):1378-80. PubMed ID: 26421390 [No Abstract] [Full Text] [Related]
17. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene. Radi E; Formichi P; Di Maio G; Battisti C; Federico A J Cell Mol Med; 2012 Aug; 16(8):1916-23. PubMed ID: 22117566 [TBL] [Abstract][Full Text] [Related]
18. Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome. Pietrzak A; Badura-Stronka M; Kangas-Kontio T; Felczak P; Kozubski W; Latos-Bielenska A; Wierzba-Bobrowicz T; Florczak-Wyspianska J Folia Neuropathol; 2019; 57(3):285-294. PubMed ID: 31588715 [TBL] [Abstract][Full Text] [Related]
19. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation. Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207 [TBL] [Abstract][Full Text] [Related]
20. The Parkinson-associated human P5B-ATPase ATP13A2 protects against the iron-induced cytotoxicity. Rinaldi DE; Corradi GR; Cuesta LM; Adamo HP; de Tezanos Pinto F Biochim Biophys Acta; 2015 Aug; 1848(8):1646-55. PubMed ID: 25912790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]